Abstract 563
Background
HNSCC occurring in previously irradiated area have a poor prognosis. With immunotherapy, the inhibition of negative regulators of immune checkpoints programmed cell death ligand-1 (PD-L1) and CD8+ tumor-infiltrating lymphocytes (TILs) have been of greatest importance for antitumor immune response. Yet, the immune landscape of pretreated area remains poorly documented and should be investigated, especially since locoregional recurrences have recently been described as a predominant site of hyperprogression. We aimed to assess the tumoral microenvironment in terms of biomarkers for tumor immune response in irradiated area compared to de novo tumors.
Methods
This retrospective monocentric study analyzed 100 HNSCC tumor tissues from patients who had undergone surgery between January 2010 and November 2017. We compared the immune microenvironment in 50 de novo tumors and 50 tumor recurrence occurring within irradiated area. Formalin-fixed and paraffin embedded tumor tissue samples were reviewed by an experimented pathologist for immunohistochemistry. We assessed p16 status, CD3+ and CD8+ TILs and PD-L1 expression on tumor and immune cells, in stromal and intratumoral components.
Results
The density of CD3+ TILs was significantly lower, whether in intratumoral or stromal region within irradiated areas (p = 0.003 and p = 0.020 respectively). The expression of CD8+ TILs was not significantly different between the two cohorts. The percentage of tumor cells expressing PD-L1 TC (TPS=1%) was significantly lower in tumours developed within irradiated area than in de novo tumors (56.0% vs 86.0%) (p < 0.001). Immune cells expressing PDL-1 were less frequent in tumors within irradiated areas. Predominant microenvironment type in irradiated area cohort was adaptative immune resistance.
Conclusions
There were persistence of cytotoxic cells and lower expression of PD-L1 and CD3+ TILs in tumors within irradiated area. This study provides first hypothesis to explain the fact that these lesions are less responsive to immunotherapy although they may still have antitumor capacity. The assessment of predictive biomarkers in patients treated by immunotherapy in randomized trials is required.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Dr Lionnel Geoffrois.
Funding
Has not received any funding.
Disclosure
C. Borel: Honoraria (self): Merck; Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy: BMS. L. Geoffrois: Honoraria (self), Travel / Accommodation / Expenses: MSD; Honoraria (self), Travel / Accommodation / Expenses: BMS; Honoraria (self): Ipsen; Honoraria (self): Novartis; Travel / Accommodation / Expenses: Merck Serono. All other authors have declared no conflicts of interest.
Resources from the same session
4692 - Immune cell biomarkers on neo-adjuvant chemo-immunotherapy treatment for resectable stage IIIA NSCLC patients
Presenter: Raquel Laza-Briviesca
Session: Poster Display session 3
Resources:
Abstract
1707 - Clinical utility of precision immunoprofiling and monitoring of the tumor microenvironment using flow cytometry and CyTOF in patients with advanced NSCLC treated with atezolizumab: results from a phase II study for biomarker analysis (EPOC1702)
Presenter: Keisuke Kirita
Session: Poster Display session 3
Resources:
Abstract
3594 - Tumor mutation burden (TMB), PD-L1, IFN-γ signaling identify subgroups of patients (pts) who benefit from durvalumab (D, anti-PDL1) or D and tremelimumab (T, anti-CTLA4) treatment in urothelial bladder cancer (UC)
Presenter: Christophe Massard
Session: Poster Display session 3
Resources:
Abstract
744 - The decrease of TMB, TNB and HLA expression are the Mechanism of Drug Resistance of NSCLC to immunosuppressive PD-1/PD-l1.
Presenter: Sheng Yu
Session: Poster Display session 3
Resources:
Abstract
2350 - Eosinophilia during treatment of immune checkpoint inhibitors (ICIs) predicts succeeding onset of immune-related adverse events (irAEs)
Presenter: Rika Kizawa
Session: Poster Display session 3
Resources:
Abstract
5930 - A transcriptomic immunologic signature predicts favorable outcome in neoadjuvant chemotherapy treated triple negative breast tumors.
Presenter: Javier Pérez-peña
Session: Poster Display session 3
Resources:
Abstract
6127 - Alterations of TMB and TCR repertoires during Chemotherapy in East Asian lung cancer patients without TKI-related driver gene mutations
Presenter: Lele Song
Session: Poster Display session 3
Resources:
Abstract
1310 - Association of SCFA in gut microbiome and clinical response in solid cancer patients treated with andi-PD-1 antibody.
Presenter: Motoo Nomura
Session: Poster Display session 3
Resources:
Abstract
2286 - Extracellular matrix and tissue derived metabolites in a liquid biopsy identifies endotypes of metastatic melanoma patients with differential response to immune checkpoint inhibitor treatment
Presenter: Nicholas Willumsen
Session: Poster Display session 3
Resources:
Abstract
4107 - Pathologic scoring of pre-treatment H&E biopsies predicts overall survival in patients with metastatic clear cell renal cell carcinoma receiving nivolumab monotherapy
Presenter: Julie Stein
Session: Poster Display session 3
Resources:
Abstract